The systemic lupus erythematosus (SLE) treatment pipeline is experiencing unprecedented expansion, driven by increasing disease awareness, rising pre ...

Although it did not meet the primary endpoint of dose-response relationship, when compared to placebo, enpatoran demonstrated improvements in measures of both systemic and cutaneous disease activity ...

Researchers have found in a recent meta-analysis that belimumab is more effective than placebo in treating systemic lupus erythematosus (SLE), based on BICLA criteria. This finding ...

Flare and persistently active disease are prevalent in a multinational cohort study of patients with systemic lupus erythematosus, with some having persistently active disease without flare.

Six of the patients, of whom four had non-renal SLE, had follow-up of at least 24 weeks. Of those, five showed dramatic ...

Inflammatory-type lesions and myelopathies found on MRI were significantly associated with attribution of neuropsychiatric events to systemic lupus erythematosus. Magnetic resonance imaging (MRI) ...

Enpatoran is a selective Toll-like receptor (TLR)7/8 inhibitor under investigation for the treatment of systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). By inhibiting ...

BARCELONA -- A novel antibody-based drug targeting the CD40 ligand helped close to half of patients with treatment-refractory systemic lupus erythematosus (SLE) get symptoms under control, according ...

The American College of Rheumatology (ACR) has released a summary of a guideline with updated recommendations for the treatment of systemic lupus erythematosus (SLE). The previous guideline for ...

New research by Swansea University and Cambridge University has revealed the causes and devastating impacts of delays—that ...